If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.
|
Tumour Group / Site |
Trial Title |
Opening Date |
|---|
| GU | Androgen Suppression with Stereotactic Body or External Beam Radiation Therapy-A Phase II Randomized Trial for Intermediate and High Risk Prostate Cancer (ASSERT) | June 2016 |
|
| |
GYNE
| Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy (AZ LIGHT D0816L00003) | May 2018
|
|
Lung | A Phase 3 Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant Medi4736 in Completely Resected Non-Small Cell Lung Cancer (CCTG BR.31) | Sept 2015 |
| Lung | A Phase II Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma (CCTG IND.227)
| Feb 2017 |
Lung
| A Randomized Trial of Durvalumab and Tremelimumab + Platinum Based Chemotherapy in Patients with High Risk Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC) CCTG BR.34 |
|
Lung
| A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU M16-298 AbbVie)
| Feb 2018
|
|
Lymphoma | Biology of Lymphoid Cancer
(Lymphoid Study) | Jan 2014 |
| Melanoma | A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) CCTG ME.13 |
July 2017
|
Myeloma
| Randomized, open label, multicenter study assessing the clinical benefit
of isatuximab combined with carfilzomib (Kyprolis®) and dexamethasone
versus carfilzomib with dexamethasone in patients with relapsed and/or
refractory multiple myeloma previously treated with 1 to 3 prior lines (Sanofi IKEMA)
| June 2018
|
Myeloma
| A Randomized Phase II, Open Label,Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma (MCRN 004)
| March 2018
|
You can view a video on participating in clinical trials that was created by staff at BC Cancer's Fraser Valley Centre.
http://learn.phsa.ca/bcca/clinicaltrials/2012oct23/ClinicalTrials2012oct23_flv_loader.html
|
